What does HELLO PHARMA do?

HELLO PHARMA is a research organisation in Liège. Private Limited, started on 5 February 2018, 1 establishment.

What is the address of HELLO PHARMA?

The registered office of HELLO PHARMA is located at Rue de Spa 15, 4020 Liège.

Is HELLO PHARMA still active?

Yes. According to the CBE (3 October 2026) HELLO PHARMA is active, legal situation “Normale toestand”, started on 5 February 2018.

Is HELLO PHARMA registered on Peppol?

Yes, HELLO PHARMA is registered on the Peppol network with ID 0208:0689779668.

What is the enterprise number of HELLO PHARMA?

The enterprise number of HELLO PHARMA is BE0689779668.

When was HELLO PHARMA founded?

HELLO PHARMA was founded on 5 February 2018.

Who are the directors of HELLO PHARMA?

According to the 2025 annual accounts, the directors of HELLO PHARMA are: Dominique NIZET, Pascal BERTHOLET.

Is HELLO PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 February 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did HELLO PHARMA make in 2025?

HELLO PHARMA posted a profit after taxes of € 101,939 in financial year 2025.

What is the revenue of HELLO PHARMA?

As a small company, HELLO PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 175,670.

HELLO PHARMA (Private Limited) - Liège - BE0689779668

Dossier HELLO PHARMA, printed on 3 October 2026 from databakkes.be/en/0689779668/hello-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HELLO PHARMA from Liège, company number BE0689779668, closed financial year 2025 with a result of € 101,939 after tax. For that financial year HELLO PHARMA recorded a gross margin of € 175,670 and equity of € 215,008. Compared with financial year 2024, the result moved from € 22,429 to € 101,939. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.

What it is worth Growing

€ 215,008

▲ 22% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 101,939

▲ € 79,509 vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 167,143

▲ 73% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 63,290 paid out

62 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 51,812

▼ 30% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 29,787

▼ 36% vs 2024

€ 14,858 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 21,325

▲ 129% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 14,592

▼ 12% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 72,052 Gross margin 2022: € 72,052 First fiscal year in the series	€ 62,975 Gross margin 2023: € 62,975 ▼ 13% vs 2022 (€ 72,052) Unfavourable step	€ 65,516 Gross margin 2024: € 65,516 ▲ 4% vs 2023 (€ 62,975) Favourable step	€ 175,670 Gross margin 2025: € 175,670 ▲ 168% vs 2024 (€ 65,516) Favourable step	▲ 168%
Profit after taxes	€ 42,637 Profit after taxes 2022: € 42,637 First fiscal year in the series	€ 28,623 Profit after taxes 2023: € 28,623 ▼ 33% vs 2022 (€ 42,637) Unfavourable step	€ 22,429 Profit after taxes 2024: € 22,429 ▼ 22% vs 2023 (€ 28,623) Unfavourable step	€ 101,939 Profit after taxes 2025: € 101,939 ▲ € 79,509 vs 2024 (€ 22,429) Favourable step	▲ € 79,509
Equity	€ 138,724 Equity 2022: € 138,724 First fiscal year in the series	€ 167,346 Equity 2023: € 167,346 ▲ 21% vs 2022 (€ 138,724) Favourable step	€ 176,359 Equity 2024: € 176,359 ▲ 5% vs 2023 (€ 167,346) Favourable step	€ 215,008 Equity 2025: € 215,008 ▲ 22% vs 2024 (€ 176,359) Favourable step	▲ 22%
Total debts	€ 130,333 Total debts 2022: € 130,333 First fiscal year in the series	€ 98,867 Total debts 2023: € 98,867 ▼ 24% vs 2022 (€ 130,333) Favourable step	€ 72,426 Total debts 2024: € 72,426 ▼ 27% vs 2023 (€ 98,867) Favourable step	€ 87,006 Total debts 2025: € 87,006 ▲ 20% vs 2024 (€ 72,426) Unfavourable step	▲ 20%
Cash	€ 127,314 Cash 2022: € 127,314 First fiscal year in the series	€ 75,637 Cash 2023: € 75,637 ▼ 41% vs 2022 (€ 127,314) Unfavourable step	€ 96,850 Cash 2024: € 96,850 ▲ 28% vs 2023 (€ 75,637) Favourable step	€ 167,143 Cash 2025: € 167,143 ▲ 73% vs 2024 (€ 96,850) Favourable step	▲ 73%
Retained profit	€ 120,124 Retained profit 2022: € 120,124 First fiscal year in the series	€ 148,746 Retained profit 2023: € 148,746 ▲ 24% vs 2022 (€ 120,124) Favourable step	€ 157,759 Retained profit 2024: € 157,759 ▲ 6% vs 2023 (€ 148,746) Favourable step	€ 196,408 Retained profit 2025: € 196,408 ▲ 24% vs 2024 (€ 157,759) Favourable step	▲ 24%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 13,416 Dividend 2024: € 13,416 Unchanged (€ 0) Unchanged	€ 63,290 Dividend 2025: € 63,290 ▲ € 49,873 vs 2024 (€ 13,416) Unchanged	▲ € 49,873
Bank debt	€ 39,693 Bank debt 2022: € 39,693 First fiscal year in the series	€ 62,565 Bank debt 2023: € 62,565 ▲ 58% vs 2022 (€ 39,693) Unfavourable step	€ 46,423 Bank debt 2024: € 46,423 ▼ 26% vs 2023 (€ 62,565) Favourable step	€ 29,787 Bank debt 2025: € 29,787 ▼ 36% vs 2024 (€ 46,423) Favourable step	▼ 36%
Balance sheet total	€ 269,056 Balance sheet total 2022: € 269,056 First fiscal year in the series	€ 266,213 Balance sheet total 2023: € 266,213 ▼ 1% vs 2022 (€ 269,056) Unchanged	€ 248,786 Balance sheet total 2024: € 248,786 ▼ 7% vs 2023 (€ 266,213) Unchanged	€ 302,014 Balance sheet total 2025: € 302,014 ▲ 21% vs 2024 (€ 248,786) Unchanged	▲ 21%

Key figures of HELLO PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HELLO PHARMA?

What happened at HELLO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 24, 2026 New annual accounts for financial year 2025: profit of € 101,939 (▲ € 79,509 vs 2024). filed late Source: NBB ↗
Mar 12, 2018 New establishment in Liège. KBO
Feb 5, 2018 Start of the company according to the CBE. KBO

In short

From € 42,637 profit in 2022 to € 101,939 profit in 2025.

Paid € 92,857 in corporate taxes since 2022.

Best year ever: 2025, with € 101,939 profit.

Paid out € 76,706 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at HELLO PHARMA? We notify you, reason included.

Follow HELLO PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Dominique NIZET Pascal BERTHOLET

HELLO PHARMA

Behind HELLO PHARMA are Dominique NIZET and Pascal BERTHOLET.

See the full network in the app

Directors

According to the 2025 annual accounts

Dominique NIZET

Director

Pascal BERTHOLET

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Spa 15

4020 Liège

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0689.779.668

VAT number

BE 0689.779.668

Registered office

Rue de Spa 15, 4020 Liège

Names & denominations

HELLO PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 February 2018

Peppol

Active · Active since 25 Nov 2025

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

HELLO PHARMA

Financials

What happened to HELLO PHARMA?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions